Graeme J Hankey. The Lancet, Early Online Publication, 11 February 2011
In The Lancet , Else Sandset and colleagues 1 report the results of the Scandinavian Candesartan Acute Stroke Trial (SCAST), in which they aimed to find out whether careful lowering of blood pressure, with the angiotensin-receptor blocker candesartan, would be beneficial in patients with acute ischaemic and haemorrhagic stroke.
The rationale for the study was that raised blood pressure is common in patients with acute stroke, associated with a poor outcome, 2 , 3 and how it should be managed is uncertain …
Weblink here